# Cirrus Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cirrus-therapeutics

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.cirrustx.com/
- Total disclosed funding: $15M
- Latest round: Seed (Aug 4, 2026)
- Investors on record: 5

## About

Founded in 2023 and based in Massachusetts, US, by CEO Ying Kai Chan and co-founder Andrew Dick, Cirrus Therapeutics Inc. operates as a biotech company providing solution for chronic blinding diseases treating the ocular immune system. In August 2026, Cirrus Therapeutics Inc. raised USD 14.7 million in seed funding from Cedars-Sinai Accelerator, ClavystBio, Polaris Partners, and SEEDS Capital. 

Cirrus Therapeutics Inc. develops treatments for long-term eye diseases that can cause blindness, focusing on conditions that affect the ocular immune system. 


The company will use the August 2026 funding to advance its ocular gene and cell therapy programs toward clinical trials.

## Funding rounds

- Seed, Aug 4, 2026, $3.7M — Polaris Partners, SEEDS Capital, Cedars-Sinai Accelerator, ClavystBio
- Seed, Oct 2, 2025, $11M — Polaris Partners, ClavystBio, Seeds

## Investors

- Polaris Partners (https://capitalatlas.ai/funds/polaris-partners) — Seed
- ClavystBio (https://capitalatlas.ai/funds/clavystbio) — Seed
- Seeds — Seed
- SEEDS Capital (https://capitalatlas.ai/funds/seeds-capital) — Seed
- Cedars-Sinai Accelerator (https://capitalatlas.ai/funds/cedars-sinai-accelerator) — Seed